Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias

Recenti Progressi in Medicina

Volumn 87, Issue 7-8, 1996, Pages 331-337

  Pini, Mario ^a,e   Scoditti, Umberto ^b   Caliumi, Fabio ^c   Manotti, Cesare ^c   Quintavalla, Roberto ^c   Pattacini, Corrado ^c   Poli, Tullio ^c   Tagliaferri, Annarita ^c   Di Iasio, Maria Grazia ^d   Bernardi, Francesco ^d  

^a Ospedale   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c V Divisione Medica e Centro Emostasi   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e NONE   (Italy)

Author keywords

congenital thrombophilias; oral contraceptives; stroke; venous thromboembolism

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN ARTERY; CONGENITAL DISORDER; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREVALENCE; RETINA VEIN; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

BIOLOGY; BLOOD PROTEINS; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE METHODS--SIDE EFFECTS; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; EUROPE; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; HEMIC SYSTEM; INCIDENCE; ITALY; LABORATORY EXAMINATIONS AND DIAGNOSES; MEASUREMENT; MEDITERRANEAN COUNTRIES; NEUROLOGIC EFFECTS; ORAL CONTRACEPTIVES--SIDE EFFECTS; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTHERN EUROPE; STUDIES; THROMBOEMBOLISM; VASCULAR DISEASES;

ADOLESCENT; ADULT; CEREBROVASCULAR DISORDERS; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; ITALY; RISK FACTORS; THROMBOEMBOLISM; THROMBOSIS;

EID: 16044363569     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-88.
3. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with different progestagen components. Lancet 1995; 346: 1589-93.
4. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593-6.
5. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, Macrae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8.
6. Lewis MA, Spitzer WO, Heinemann LAJ, Macrae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90.
7. Farmer RTD, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995; 15: 195-200.
8. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
9. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
10. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
12. Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulant (ISLA-1). Thromb Haemost 1990; 64: 478-84.
13. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived aminoacid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846- 50.
14. Rothman KJ. Modern epidemiology. Boston: Little Brown 1986.
15. Stampfer MJ, Willet WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1313-7.
16. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987; 69: 91-5.
17. Brill K, Norpoth T, Schnitker J, Albring M. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users. Contraception 1991; 43: 101-10.
18. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptives users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-57.
19. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986; 292: 526.
20. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BW, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7.
21. Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985; 66: 1-4.
22. Porter JB, Hunter JR, Danielson DA, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Recent experience. Obstet Gynecol 1982; 59: 299-302.
23. Berkson J. Limitations of the applications of fourfold table analysis to hospital data. Biometrics 1946; 2: 47-53.
24. Lidegaard Ø. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 1993; 306: 956-63.
25. Hart RG, Miller VT. Cerebral infarction in young adults: a practical approach. Stroke 1983; 14: 110-4.
26. Oleckno WA. The risk of stroke in young adults. An analysis of the contribution of cigarette smoking and alcohol consumption. Public Health 1988; 102: 45-55.
27. Thorogood M, Mann J, Murphy M, Vessey M. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol 1992; 136: 35-45.
28. rd ed. Philadelphia: JB Lippincott 1994; 1255-73.
29. Lobo RA. Estrogen and the risk of coagulopathy. Am J Med 1992; 92: 283-5.
30. Robinson GE, Burren T, Mackie IJ, et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. Brit Med J 1991; 302: 269-71.
31. Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524-5.
32. Bridey F, Wolff M, Laissy JP, et al. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995; 74: 1382.